company background image
BGNE

BeiGene NasdaqGS:BGNE Stock Report

Last Price

US$179.82

Market Cap

US$18.6b

7D

-6.0%

1Y

-38.0%

Updated

17 Aug, 2022

Data

Company Financials +
BGNE fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

BGNE Stock Overview

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide.

BeiGene, Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for BeiGene
Historical stock prices
Current Share PriceUS$179.82
52 Week HighUS$426.56
52 Week LowUS$118.18
Beta0.66
1 Month Change4.10%
3 Month Change36.57%
1 Year Change-37.99%
3 Year Change23.13%
5 Year Change161.52%
Change since IPO534.96%

Recent News & Updates

Aug 15

BeiGene, McKesson team up to develop data, tools for US community oncology care

BeiGene (NASDAQ:BGNE) signed a strategic agreement with McKesson's (NYSE:MCK) unit Ontada to improve U.S. community oncology care by developing real-world evidence (RWE) data and tools to help increase access to affordable therapies. The partnership will be led by Ontada and focus on developing and implementing RWE to improve community education on the financial impact and value of oncolytics and improve patient access to oncology medicines, BeiGene said in an Aug. 15 press release. "BeiGene aims to bring 10 molecules per year to the clinic starting in 2023 and, as this research advances, we’re delighted to form this strategic partnership with McKesson, which shares the same vision as BeiGene for improving the care of cancer patients," said Christiane Langer, senior vice president of Global Medical Affairs, ex-China, BeiGene.

Aug 09

Novartis/BeiGene's tislelizumab matches Bayer's Nexavar in survival benefit for liver cancer patients in trial

BeiGene (NASDAQ:BGNE) and Novartis' (NYSE:NVS) tislelizumab met the main goal of being as good as Bayer's (OTCPK:BAYZF) (OTCPK:BAYRY) Nexavar (sorafenib) in improving overall survival (OS) of patients with a type of liver cancer in a phase 3 trial. The study, dubbed RATIONALE 301, evaluated tislelizumab against sorafenib as a first-line therapy in adult patients with unresectable hepatocellular carcinoma (HCC). More than 600 patients in the U.S., Europe, and Asia were in the study. BeiGene (BGNE) said that the the safety profile for tislelizumab was consistent with previous studies and no new safety signals were reported.

Shareholder Returns

BGNEUS BiotechsUS Market
7D-6.0%-2.0%1.1%
1Y-38.0%-23.0%-9.0%

Return vs Industry: BGNE underperformed the US Biotechs industry which returned -22.2% over the past year.

Return vs Market: BGNE underperformed the US Market which returned -8.9% over the past year.

Price Volatility

Is BGNE's price volatile compared to industry and market?
BGNE volatility
BGNE Average Weekly Movement12.0%
Biotechs Industry Average Movement12.3%
Market Average Movement7.6%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.1%

Stable Share Price: BGNE is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: BGNE's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
20108,600John Oylerhttps://www.beigene.com

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin’s lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company’s clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors.

BeiGene, Ltd. Fundamentals Summary

How do BeiGene's earnings and revenue compare to its market cap?
BGNE fundamental statistics
Market CapUS$18.61b
Earnings (TTM)-US$2.01b
Revenue (TTM)US$1.07b

17.4x

P/S Ratio

-9.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BGNE income statement (TTM)
RevenueUS$1.07b
Cost of RevenueUS$1.78b
Gross Profit-US$714.29m
Other ExpensesUS$1.29b
Earnings-US$2.01b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-19.38
Gross Margin-66.84%
Net Profit Margin-187.65%
Debt/Equity Ratio10.7%

How did BGNE perform over the long term?

See historical performance and comparison